Similar Articles |
|
Pharmaceutical Executive March 1, 2011 Jerry Coamey |
Engage the Physician! New research shows that gauging the mind of the clinician is crucial to timely uptake of the new diagnostic tools offered by the genomic revolution |
Fast Company David Lumb |
Sites That Sell Cancer Gene Tests Don't Tell Customers The Whole Story, Study Finds Consumer tests that analyze DNA from tumors in order to help personalize a patient's treatment are in something of a Wild West period. |
The Motley Fool February 4, 2010 Brian Orelli |
Surfing the Wave of the Future: Personalized Medicine Medco buys in to personalized medicine. Yesterday Medco Health Solutions said it's purchasing genetic-testing expert DNA Direct. |
Pharmaceutical Executive September 1, 2010 |
The Testing of the Tests FDA seeks to regulate genetic tests more actively, while encouraging diagnostic development. |
Chemistry World July 2010 Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition. |
Chemistry World February 25, 2015 Rebecca Trager |
US opens up home DNA screening The US Food and Drug Administration has, for the first time, authorized a genetic test to be sold directly to consumers. The agency plans to ease the regulatory path for similar screening tests. |
The Motley Fool June 14, 2010 Bruce Bigelow |
Genetic Testing Companies in San Diego, Boston, and San Francisco Studying FDA Letters The letters notify the companies that genome-sequencing tests they offer to consumers are medical devices that require the agency's approval. |
Managed Care May 2001 Michael D. Dalzell |
Powerful Opportunities For Good and Greed Genetic advances could spawn incredible improvements in health care. Given public demand, they also pose what may be unmanageable issues of resource use... |
Bio-IT World March 17, 2004 Zachary Zimmerman |
Testing Times for the FDA The FDA's pharmacogenomic guidance marks the beginning of a long process toward standardized tests. |
Pharmaceutical Executive September 1, 2011 Don Creighton |
Bridging the Hidden Hurdle in Cancer Cures Diagnostics can boast the efficacy of drug treatments, but delivering the promise depends on a predictable pathway to reimbursement. |
Bio-IT World August 13, 2003 John Rhodes |
Beyond the Blockbuster Genomics and big hits are not mutually exclusive, writes Deloitte & Touche's life sciences expert. |
The Motley Fool December 30, 2008 Brian Orelli |
A Post-Holiday Breakup ... of Sorts Abbott and Celera revise their partnership. |
The Motley Fool May 28, 2010 Brian Orelli |
Is It Time to Make Money Investing in Genetic Testing? Easier said than done. |
The Motley Fool July 9, 2008 Brian Lawler |
Predicting More Good News From Invitrogen Invitrogen gets a positive review from the FDA for one of its tests. |
Chemistry World September 11, 2013 Emma Stoye |
Call to overhaul liver toxicity testing Outdated assays for monitoring liver health could have caused dozens of drug candidates to be wrongly scrapped during development, according to new research. |
Managed Care November 2006 Maureen Glabman |
Genetic Testing: Major Opportunity, Major Problems Whether a person is likely to develop diabetes, cancer, schizophrenia, or stroke will be reasonably well predicted, and tests can also determine whether a patient will respond to a given therapy. That's the good part. |
The Motley Fool June 20, 2008 Brian Orelli |
Live From Bio: Personalized Medicine The movement is chugging along thanks to diagnostics. |
Fast Company David Lumb |
The FDA Just OK'd 23AndMe To Test For One Syndrome The FDA just gave consumer genetics testing company 23AndMe permission to sell tests for Bloom syndrome -- a disease associated with shortened height and an increased cancer risk. |
Bio-IT World December 15, 2003 Kevin Davies |
The Road to Personalized Medicine FDA guidance on the road to genomic medicine is a welcome first step in what promises to be a contentious debate on how to integrate pharmacogenomics into routine medical practice. |
Pharmaceutical Executive February 1, 2013 William Looney |
In Cancer, Process Drives Progress Today's most important public health story is the advance in our understanding of the biology of cancer. |
BusinessWeek September 5, 2005 Kerry Capell |
Meeting Leukemia's Diagnostic Challenge Tests that distinguish among the disease's many forms either cost too much or don't exist. Dr. Torsten Haferlach And Switzerland's Roche Diagnostics may have a solution. |
Chemistry World March 2, 2007 Arthur Rogers |
Drug Misuse Under Investigation European drug crime experts have been commissioned by the Council of Europe Parliamentary Assembly to investigate ways of combating the increased use of date rape drugs such as Rohypnol. |
Managed Care September 2002 |
Aetna Chief Wants Coverage For Genetic Tests The CEO of the country's largest for-profit HMO has jumped with both feet into the national discussion about genetic testing's place in health care. |
Managed Care May 2005 Martin Sipkoff |
Predictive Modeling & Genomics: Marriage of Promise and Risk Integration of predictive modeling and genomic tools means improved technology, enhanced databases, and appropriate legal guidance. |
Pharmaceutical Executive June 1, 2006 Nancy Dreyer |
Personalized Medicine Meets the Real World A wave of genomic medicines is coming down the pipeline, and they're going to be expensive. Can companies prove they're worth it? Maybe: but the claims payers seek aren't coming from traditional clinical trials. |
BusinessWeek September 5, 2005 Capell & Arndt |
Drugs Get Smart Future medicines will more effectively target what ails you by tailoring treatment to your specific genetic profile. Personalized medicine will also help prevent another Vioxx. |
Bio-IT World November 14, 2003 Kathy Ordonez |
Targeted Medicine via Molecular Diagnostics Using diagnostics to select and deselect target populations for drug therapy will enable life scientists to make more effective medicines. |
Managed Care April 2005 Michael Levin-Epstein |
Time To Decipher Legislation's DNA Health plans have much at stake as Congress moves to lay down the do's and don'ts about use of info gathered via genetic testing. |
The Motley Fool September 7, 2007 Brian Orelli |
Clinical Data Gets Personal Clinical Data's lead compound Vilazodone posts strong phase 3 results. The company is searching for common genetic markers among patients who responded positively to the drug. |
The Motley Fool March 31, 2010 Brian Orelli |
When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies. |
Managed Care June 2001 Darcy Lewis |
National Guideline Clearinghouse: Extensive Resource Underused It's there on the Web, highly convenient. What keeps physicians away? |
Managed Care September 2004 Tony Berberabe |
Can Physician and Health Plan Get Together Over Guidelines? Physicians are not the only problem. Health plans too often view guidelines as rigid routines rather than flexible aids to good practice. |
Fast Company September 2000 John Ellis |
The Secret of Life The mapping of the human genome, says Craig Venter, will change science, research, medicine, politics, health insurance, and the way biology looks at the last 3 billion years of evolution. And that's just the beginning. |
Entrepreneur January 2006 Jacquelyn Lynn |
The DNA Dilemma Should genetic discrimination be part of your employment practices liability insurance coverage? |
The Motley Fool October 27, 2010 Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
AskMen.com Jacob Franek |
Genetic Testing Every day the prospect of individualized genetic testing is slowly becoming commonplace, and certain questions about genetic testing are apparent: What kinds of tests are available? Where can I get them? How accurate are they? And what are the costs? |
Bio-IT World February 2007 Kevin Davies |
Obama Declares for Personalized Medicine Barack Obama is one of few members of congress who sees the genomics tidal wave and is doing something about it. Obama may be a Democrat, but drug and biotech industries have reason to hope. |
The Motley Fool September 28, 2007 Brian Orelli |
Side Effects No Match for This Tag Team Seven large drugmakers have come together to try and find genetic variations that cause medications to have serious side effects in some patients, but not in others. |
Fast Company January 2002 George Anders |
Roche's New Scientific Method How does a giant pharmaceutical company reckon with genomics technology? By making a fresh start in how it recruits its scientists, manages projects, and uses computers. Here's how the Roche Group is reinventing how it invents... |
The Motley Fool September 24, 2007 Jack Uldrich |
Nanotech Is in the Genes The FDA's stamp of approval on a genetic test that will help patients better understand how they will metabolize anti-blood clot medication gives Nanosphere extra allure. Investors should take note. |
Chemistry World May 29, 2014 Darren Smyth |
We need to talk about Nagoya On 14 April 2014, the Council of the EU adopted a regulation that will affect researchers throughout Europe, by enabling ratification of the Nagoya Protocol. |
Fast Company Elizabeth Segran |
23andMe And The FDA Reached A Pivotal Genetic Testing Agreement An FDA decision summary allows DNA-testing company 23andMe to market a genome test that screens for Bloom syndrome, a rare disorder that may lead toward the development of cancer. |
Chemistry World December 24, 2014 Rebecca Trager |
FBI's 2001 anthrax investigation was flawed The scientific evidence that the US Federal Bureau of Investigation relied upon to investigate the October 2001 anthrax attacks was deeply flawed, according to a new report. |
Nurse Practitioner February 2010 Andrews et al. |
ARVC: Help prevent sudden death Arrhythmogenic right ventricular cardiomyopathy is a dangerous condition that can cause sudden death. |
The Motley Fool August 17, 2007 Brian Orelli |
FDA's Rigor May Boost Sales The FDA is updating labeling of certain blood-thinning drugs, indicating that patients may want to obtain a genetic test prior to taking the medication. This move may lead to increased testing, and hopefully increased prescriptions. |
The Motley Fool August 24, 2007 Brian Orelli |
Take Your Medicine; Earn Your Profits Personalized medicine offers investment ideas. Let's take a look at what this new catchphrase in the medical community actually means, and how investors can benefit from it. |
IEEE Spectrum March 2013 Eliza Strickland |
The Gene Machine and Me Ion Torrent's chip-based genome sequencer is cheap, fast, and poised to revolutionize medicine |
Chemistry World March 25, 2010 Leila Sattary |
Science advice rules published The publication of the long-awaited principles for scientific advice in government has met with a frosty response, with some U. K. critics calling for researchers to boycott the guidelines. |
Scientific American November 2007 |
Reviews Few books could present more implacably opposed views, and few could raise more provocative questions: The Case Against Perfection: Ethics in the Age of Genetic Engineering by Michael J. Sandel... Enhancing Evolution: The Ethical Case for Making Better People by John Harris... |
Chemistry World January 28, 2015 Rebecca Trager |
Roche chases bolt-on acquisitions as it pushes into genomics A recent spending spree by Roche is intended to take advantage of emerging molecular information and genomic analysis, as the company anticipates that the field will play an increasingly important role for future medicines and diagnostics. |